Affiliation:
1. Department of Microbiology, Biochemistry & Immunology, Morehouse School of Medicine, Atlanta, GA 30310, USA
2. RCMI Cancer Research Center, Department of Chemistry, New Orleans, LA 70125, USA
Abstract
This review specifically examines the important function of the oncoprotein FOSL1 in the dimeric AP-1 transcription factor, which consists of FOS-related components. FOSL1 is identified as a crucial controller of invasion and metastatic dissemination, making it a potential target for therapeutic treatment in cancer patients. The review offers a thorough examination of the regulatory systems that govern the influence exerted on FOSL1. These include a range of changes that occur throughout the process of transcription and after the translation of proteins. We have discovered that several non-coding RNAs, such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), play a significant role in regulating FOSL1 expression by directly interacting with its mRNA transcripts. Moreover, an investigation into the functional aspects of FOSL1 reveals its involvement in apoptosis, proliferation, and migration. This work involves a comprehensive analysis of the complex signaling pathways that support these diverse activities. Furthermore, particular importance is given to the function of FOSL1 in coordinating the activation of several cytokines, such as TGF-beta, and the commencement of IL-6 and VEGF production in tumor-associated macrophages (TAMs) that migrate into the tumor microenvironment. There is a specific emphasis on evaluating the predictive consequences linked to FOSL1. Insights are now emerging on the developing roles of FOSL1 in relation to the processes that drive resistance and reliance on specific treatment methods. Targeting FOSL1 has a strong inhibitory effect on the formation and spread of specific types of cancers. Despite extensive endeavors, no drugs targeting AP-1 or FOSL1 for cancer treatment have been approved for clinical use. Hence, it is imperative to implement innovative approaches and conduct additional verifications.
Reference118 articles.
1. Emerging therapies for glioblastoma: Current state and future directions;Rong;J. Exp. Clin. Cancer Res.,2022
2. Biserova, K., Jakovlevs, A., Uljanovs, R., and Strumfa, I. (2021). Cancer Stem Cells: Significance in Origin, Pathogenesis and Treatment of Glioblastoma. Cells, 10.
3. Replication Stress Drives Constitutive Activation of the DNA Damage Response and Radioresistance in Glioblastoma Stem-like Cells;Carruthers;Cancer Res.,2018
4. The role of FOSL1 in stem-like cell reprogramming processes;Pecce;Sci. Rep.,2021
5. fra-1: A serum-inducible, cellular immediate-early gene that encodes a fos-related antigen;Cohen;Mol. Cell. Biol.,1988